Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27904455 | 0.87 | ACACB (0.49) | LMNASMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL19566180 | 0.87 | ACACB (0.49) | LMNASMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL4333892 | 0.80 | NPC1 (0.49) | LMNANPC1RAB9AALDH1A1ESR1 | |
| SCHEMBL4897519 | 0.79 | NPC1 (0.45) | SMN1; SMN2NPC1RAB9APPARGPPARA | |
| SCHEMBL14208222 | 0.77 | PPARG (0.53) | LMNASMN1; SMN2NPC1RAB9APPARG | |
| SCHEMBL1454266 | 0.77 | PPARG (0.53) | LMNASMN1; SMN2NPC1RAB9APPARG | |
| SCHEMBL25438243 | 0.77 | CNR1 (0.43) | LMNASMN1; SMN2NPC1RAB9APPARG | |
| SCHEMBL2543698 | 0.77 | NPC1 (0.79) | LMNASMN1; SMN2NPC1RAB9AALDH1A1 | |
| SCHEMBL24609344 | 0.77 | NPC1 (0.79) | LMNASMN1; SMN2NPC1RAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL23524428 | 0.75 | TAAR1 (0.52) | LMNASMN1; SMN2NPC1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170029406-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | ATTUNE PHARMACEUTICALS, INC. | 2017-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170029406-A1 | THERAPEUTIC INHIBITORY COMPOUNDS | KLKB1, SERPINB1, SERPINE1 | LMNA 2032/4885SMN1; SMN2 4577/4885NPC1 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.